Apogee Therapeutics, Inc. (APGE) Stock Overview
Explore Apogee Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Apogee Therapeutics, Inc. (APGE)
Key Financials
Key Financials
Market Cap
8.3B
P/E Ratio
-30.98
EPS (TTM)
$-4.33
ROE
-0.33%
APGE Stock Analysis & Investment Overview (NASDAQ)
Our AI-powered analysis of Apogee Therapeutics, Inc. (NASDAQ: APGE) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, Apogee Therapeutics, Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.
The current technical analysis of APGE on the NASDAQ shows an RSI of 79.44, suggesting the stock is in a an overbought condition. Our forecasting models predict a 12-month price target of $91.99 for the NASDAQ listing.
Key metrics behind Apogee Therapeutics, Inc.'s NASDAQ-traded stock include a P/E ratio of -30.98 and a market capitalization of 8.3B. Combined with our AI analysis, these give both institutional and retail investors a clear view of APGE on the NASDAQ.